Xanthistop 120 mg 30 tablets

Tradename:

xantistop

Xanthistop

Compound:

Each tablet contains:

Febuxostat 120 mg

Auxiliary components:

Lactose monohydrate, hypromellose, microcrystalline cellulose (Avicel PH 101), lactose monohydrate cellulose, hypromellose, microcrystalline cellulose (Avicel PH 101), croscarmellose sodium, magnesium stearate, aqueous colloidal silicon dioxide.

Properties:

Selective non-purine xanthine oxidase inhibitor, 2-arylthiazole derivative.

The enzyme xanthine oxidase catalyzes two steps of purine metabolism: the oxidation of hypoxanthine to xanthine and then the oxidation of xanthine to uric acid.

As a result of selective inhibition of xanthine oxidase (oxidized and reduced forms) by febuxostat, a decrease in the concentration of uric acid in the blood serum occurs. The in vitro inhibition constant is less than 1 nM.

Indications:

Treatment of chronic hyperuricemia in conditions accompanied by the deposition of urate crystals (in the presence of tophi and / or gouty arthritis, including a history).

Treatment and prevention of hyperuricemia in adult patients during cytostatic therapy of hemoblastoses with a moderate to high risk of developing tumor disintegration syndrome (only for a dose of 120 mg).

Dosage and administration:

The optimal dosage regimen is determined by the doctor. Compliance of the dosage form of a particular drug with indications for use and dosing regimen should be strictly observed.

Taken inside.

The dose is 80-120 mg 1 time / day. The duration of treatment is set individually, depending on the indications.

The goal of treatment is to lower and maintain serum uric acid levels below 6 mg/dL (357 µmol/L).

Contraindications:

Pregnancy, breastfeeding period; children’s age up to 18 years; hypersensitivity to febuxostat.

Precautionary measures:

Febuxostat should only be started after an acute attack of gout has resolved. The use of febuxostat can provoke the development of an acute attack of gout due to the release of urate from tissue depots and a subsequent increase in the concentration of uric acid in the blood serum. For the prevention of gout attacks, the simultaneous use of NSAIDs or colchicine for at least 6 months is recommended.

Influence on the ability to drive vehicles and mechanisms:

When using febuxostat, drowsiness, dizziness, paresthesia and blurred vision may occur, and, as a result, a decrease in reaction and ability to concentrate, therefore, during the period of treatment, care should be taken when driving vehicles and engaging in other potentially hazardous activities that require concentration and speed of psychomotor reactions.

Side effects:

On the part of the hematopoietic system: infrequently – a decrease in the number of platelets, leukocytes.

From the nervous system: often – headache.

From the side of metabolism: often – attacks of gout; infrequently – diabetes mellitus, hyperlipidemia, loss of appetite, weight gain.

On the part of the psyche: infrequently – decreased libido, insomnia; rarely – nervousness.

On the part of the organ of vision: rarely – blurred vision.

On the part of the organ of hearing and labyrinth disorders: rarely – tinnitus.

Since the cardiovascular system: infrequently – atrial fibrillation, palpitations.

From the digestive system: often – diarrhea (more often with the simultaneous use of colchicine), nausea.

From the side of the liver and biliary tract: often – a violation of liver function (more often with the simultaneous use of colchicine).

On the part of the skin and subcutaneous tissues: often – a rash (including various types of rashes mentioned below with a lower frequency); infrequently – dermatitis, urticaria, pruritus.

General reactions: often – edema; infrequently – increased fatigue, chest pain, discomfort in the chest area.

Storage method:

Store at a temperature not exceeding 30 degrees.

Package:

Cardboard box contains 3 blisters of 10 tablets, paper instructions.